olivLaw · US equity research
Ridgetech, Inc. RDGT
Retail-Drug Stores and Proprietary Stores · SIC 5912 · Vertical: Miscellaneous retail (SIC 59xx)
Ridgetech is a wholesale distributor of pharmaceutical and medical products in China that exited the retail pharmacy business in February 2025 and now focuses on offline and online wholesale, expanded through the Allright acquisition. For fiscal 2026 the company reported revenue of 132.2 mn USD, but with a very thin gross margin and operating losses, so the performance of the online division is a point to watch.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Ridgetech, Inc. (RDGT) stock was 0.75 USD (−4.36% on the day), with market capitalisation 99.3 m USD, beta 0.78, 52-week range 0.71–760.50 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 39.2
- weak (30–45)
- Bollinger (20, 2)
- 0.73 – 0.94
- in the lower half of the band · %B 0.08 · band width 25.7%
- SMA 50 / 200
- 0.87 / 68.76
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.03 / -0.02
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −19.8% | −5.9% | −13.8 pp | — |
| 3 months | −5.6% | −4.6% | −0.9 pp | — |
| 6 months | −49.3% | +0.2% | −49.5 pp | — |
| Year to date | −99.8% | +7.4% | −107.2 pp | — |
| 1 year | −99.7% | +8.2% | −107.9 pp | −25.6% |
| 3 years | −99.9% | +68.4% | −168.3 pp | +1.7% |
| 5 years | −100.0% | +56.5% | −156.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 117.3 m | 133.1 m | 164.4 m | 120.2 m | 124.0 m | 120.0 m | 132.2 m |
| Revenue YoY | unavailable | +13.5% | +23.5% | −26.9% | +3.2% | −3.2% | +10.2% |
| Net income | -5.8 m | -8.1 m | -3.2 m | -21.1 m | -4.2 m | 10.2 m | -1.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | −112.3% |
| Diluted EPS | -2.16 | -2.39 | -18.35 | -41.46 | -439.78 | 275.87 | -17.21 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | −106.2% |
| net % | -5.0% | -6.1% | -1.9% | -17.6% | -3.4% | 8.5% | -0.9% |
| Free cash flow | -7.6 m | -189.1 k | -5.5 m | -3.4 m | -3.5 m | 1.1 m | -1.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2026 · 31 Mar 2026
- Cash
- 17.9 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 40.8 m USD
- Total assets
- 69.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 2.31x
- ROE
- -3.6%
- ROA
- -1.9%
- FCF margin
- -1.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 133.1 m | 164.4 m | 120.2 m | 124.0 m | 120.0 m | 132.2 m | SEC (XBRL)· 31 Jul 2026verified |
| Cost of revenue | 133.1 m | 164.4 m | 148.8 m | 119.1 m | 116.1 m | 127.4 m | SEC (XBRL)· 31 Jul 2026verified |
| Gross profit | 29.2 m | 36.5 m | 3.6 m | 4.9 m | 3.8 m | 4.8 m | SEC (XBRL)· 31 Jul 2026verified |
| Operating income | -8.8 m | -2.7 m | -13.2 m | 596.1 k | -1.0 m | -1.9 m | SEC (XBRL)· 31 Jul 2026verified |
| Depreciation & amortisation | 1.8 m | 1.3 m | 718.0 k | 790.4 k | 1.1 m | 363.7 k | SEC (XBRL)· 31 Jul 2026verified |
| EBITDA | -7.1 m ≈ | -1.4 m ≈ | -12.4 m ≈ | 1.4 m ≈ | 101.9 k ≈ | -1.5 m ≈ | SEC (XBRL)· 31 Jul 2026derived |
| Interest expense | 455.2 k | 262.2 k | -31.6 k | -197.8 k | -92.8 k | 67.1 k | SEC (XBRL)· 31 Jul 2026verified |
| Pre-tax income | -8.3 m | -2.1 m | -15.4 m | -827.1 k | -950.7 k | -1.3 m | SEC (XBRL)· 31 Jul 2026verified |
| Income tax | 31.6 k | 1.1 m | 394.5 k | -41.4 k | 503.5 k | -99.1 k | SEC (XBRL)· 31 Jul 2026verified |
| Net income | -8.1 m | -3.2 m | -21.1 m | -4.2 m | 10.2 m | -1.3 m | SEC (XBRL)· 31 Jul 2026verified |
| Diluted EPS | -2.39 | -18.35 | -41.46 | -439.78 | 275.87 | -17.21 | SEC (XBRL)· 31 Jul 2026verified |
| Weighted average diluted shares | 3.4 m | 174.0 k | 509.8 k | 9.6 k | 37.0 k | 72.7 k | SEC (XBRL)· 31 Jul 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 22.0 m | 18.5 m | 18.8 m | 2.3 m | 12.8 m | 17.9 m | SEC (XBRL)· 31 Jul 2026verified |
| Receivables | 13.4 m | 16.7 m | 14.1 m | 6.0 m | 27.8 m | 32.5 m | SEC (XBRL)· 31 Jul 2026verified |
| Inventories | 17.0 m | 16.0 m | 15.3 m | 9.1 m | 9.8 m | 8.3 m | SEC (XBRL)· 31 Jul 2026verified |
| Current assets | 72.2 m | 75.4 m | 64.5 m | 69.7 m | 59.7 m | 64.6 m | SEC (XBRL)· 31 Jul 2026verified |
| Property, plant & equipment, net | 6.5 m | 5.9 m | 5.1 m | 8.4 k | 8.9 k | 5.7 k | SEC (XBRL)· 31 Jul 2026verified |
| Goodwill | — | — | — | — | 1.5 m | 1.5 m | SEC (XBRL)· 31 Jul 2026verified |
| Intangibles (excl. goodwill) | 3.5 m | 3.5 m | 3.2 m | 1.3 m | 3.3 m | 3.0 m | SEC (XBRL)· 31 Jul 2026verified |
| Total assets | 106.3 m | 106.4 m | 91.0 m | 95.1 m | 64.5 m | 69.0 m | SEC (XBRL)· 31 Jul 2026verified |
| Accounts payable | — | — | 27.0 m | 30.6 m | 19.7 m | 22.8 m | SEC (XBRL)· 31 Jul 2026verified |
| Short-term debt | 762.3 k | — | — | 277.0 k | — | — | SEC (XBRL)· 30 Jul 2024verified |
| Long-term debt | 1.9 m | — | — | — | — | — | SEC (XBRL)· 28 Jul 2022verified |
| Current liabilities | 64.9 m | 74.4 m | 66.5 m | 74.4 m | 34.4 m | 27.9 m | SEC (XBRL)· 31 Jul 2026verified |
| Total liabilities | 81.9 m | 83.6 m | 74.3 m | 80.8 m | 34.8 m | 28.3 m | SEC (XBRL)· 31 Jul 2026verified |
| Equity | 24.4 m | 22.7 m | 16.7 m | 14.3 m | 29.6 m | 40.8 m | SEC (XBRL)· 31 Jul 2026verified |
| Shares outstanding at year end | — | 3.5 m | 23.7 m | 1.7 m | 5.9 m | 133.1 m | SEC (XBRL)· 31 Jul 2026verified |
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -62.3 k | -5.4 m | -3.3 m | -3.2 m | 1.2 m | -1.4 m | SEC (XBRL)· 31 Jul 2026verified |
| Capex | 126.8 k | 90.0 k | 118.3 k | 330.7 k | 155.4 k | 449 | SEC (XBRL)· 31 Jul 2026verified |
| Free cash flow | -189.1 k ≈ | -5.5 m ≈ | -3.4 m ≈ | -3.5 m ≈ | 1.1 m ≈ | -1.4 m ≈ | SEC (XBRL)· 31 Jul 2026derived |
| Investing cash flow | -2.0 m | -306.1 k | -316.1 k | -2.0 m | -18.1 m | -449 | SEC (XBRL)· 31 Jul 2026verified |
| Financing cash flow | 3.1 m | 4.8 m | 2.4 m | 8.0 m | 1.5 m | -29.7 k | SEC (XBRL)· 31 Jul 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 99.3 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -0.9% | 42 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 3.2% | 27 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -27.8x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 2.3x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -1.4% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial27/100 · 1/2 factors with a value
- Quality· partial42/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Ridgetech, Inc. (RDGT). Latest full fiscal year: 2026; data up to 2026-03-31.
Figures computed from the financial statements: revenue 132.2 m USD in 2026; YoY growth 10.2%; net margin -0.9%; ROE -3.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.3x
What contradicts it
- Revenue CAGR 3Y: 3.2%
- Interest coverage: -27.8x
- FCF yield: -1.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Miscellaneous retail (SIC 59xx) · same major group (2-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMZNAmazon.com, Inc. | 2,813.7 bn | 21.0 | 27.4% | 16.9% | +12.4% | +12% / +78% |
| CVSCVS HEALTH Corp | 104.1 bn | 9.5 | 14.4% | 2.6% | +7.8% | +1% / +20% |
| ULTAUlta Beauty, Inc. | 27.8 bn | 23.7 | 46.1% | 9.3% | +9.7% | +21% / +53% |
| CDWCdw Corp | 19.8 bn | 18.5 | 42.5% | 4.5% | +6.8% | +10% / −25% |
| NSITInsight Enterprises, Inc. | 4.4 bn | 25.7 | 11.5% | 2.0% | −5.2% | +76% / +1% |
| REALTheRealReal, Inc. | 1.6 bn | — | — | -1.4% | +15.4% | −10% / +475% |
| JMIAJumia Technologies AG | 1.3 bn | — | -108.9% | -32.6% | +12.8% | −60% / +51% |
| WINAWinmark Corporation | 956.0 m | 24.0 | — | 45.1% | +5.9% | −35% / −38% |
| GCTGigacloud Technology Inc | 587.7 m | 13.6 | 33.1% | 10.9% | +11.1% | +70% / +548% |
| LITBLightInTheBox Holding Co., Ltd. | 581.7 m | 67.0 | — | 3.7% | −12.1% | +40% / −64% |
| HNSTThe Honest Company, Inc. | 484.3 m | 6.6 | 34.6% | 23.5% | −1.9% | +65% / +86% |
| BNEDBarnes & Noble Education, Inc. | 434.7 m | 19.6 | 8.3% | 1.3% | +6.5% | +34% / −89% |
| BBWBuild-A-Bear Workshop Inc | 364.4 m | 7.3 | 32.8% | 10.0% | +6.7% | −44% / +21% |
| TMSTeamshares Inc | 349.9 m | — | -6.7% | — | unavailable | −54% / unavailable |
| NEGGNewegg Commerce, Inc. | 194.0 m | — | -3.7% | -0.3% | +16.9% | −88% / −63% |
| TDUPThredUp Inc. | 192.6 m | — | -39.2% | -6.9% | +19.5% | −81% / −26% |
| PLBYPlayboy, Inc. | 145.4 m | 55.7 | 10.8% | 1.3% | +4.1% | −35% / +136% |
| RDGTRidgetech, Inc. | 99.3 m | — | -3.6% | -0.9% | +10.2% | −100% / −100% |
| BARKBark, Inc. | 74.5 m | — | -30.8% | -6.9% | −18.5% | −42% / −49% |
| HEREHere Group Limited | 70.3 m | 7.5 | 9.1% | 10.6% | −76.9% | −71% / −24% |
| HOURHour Loop, Inc. | 53.3 m | 36.7 | 21.8% | 1.1% | +3.0% | −29% / +2% |
| GROVGrove Collaborative Holdings, Inc. | 44.8 m | — | — | -4.1% | −14.6% | −23% / −47% |
| SPWHSportsman’s Warehouse Holdings, Inc. | 43.1 m | — | -25.8% | -3.9% | +1.0% | −51% / −77% |
| LIVELIVE VENTURES Inc | 23.0 m | — | -2.8% | -0.6% | −5.9% | −19% / −70% |
| GIFTGiftify, Inc. | 18.8 m | — | -36.2% | -8.8% | −6.5% | −53% / −87% |
1- and 3-year price returns: for RDGT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 31 Jul 2026; since then the company filed 6-K (09 Sept 2026), 6-K (01 Sept 2026), 6-K (28 Aug 2026), 6-K (05 Aug 2026).
In brief
Ridgetech is a wholesale distributor of pharmaceutical and medical products in China that exited the retail pharmacy business in February 2025 and now focuses on offline and online wholesale, expanded through the Allright acquisition. For fiscal 2026 the company reported revenue of 132.2 mn USD 1, but with a very thin gross margin and operating losses, so the performance of the online division is a point to watch 1.
SWOT
Strengths
- The company has a broad product range with many references and a large number of small customers, reached both offline and online 1.
- The Allright acquisition brought a consolidated online platform and wider geographic coverage, with its own sales team and logistics network 1.
- Exiting retail pharmacies simplified the business model and focused the company on wholesale distribution 1.
Weaknesses
- Gross margins are extremely thin and the company has little bargaining power over prices 1.
- The company reported operating losses in fiscal 2026 and disclosed material weaknesses in internal control 1.
- Reliance on one major customer and a supply agreement with a single pharmacy makes revenue vulnerable if that relationship changes 1.
Opportunities
- Growth in the online channel and integration of Allright could lift the share of sales through national platforms 1.
- If the company gains exclusive agency status for popular drugs or access to large hospitals, it could improve margins 1.
- Expanding the base of small customers, who often ask the company for guidance, could build loyalty and repeat sales 1.
Threats
- Intense competition from larger distributors with superior financial and logistics resources could keep pressing prices down 1.
- The risk of counterfeit pharmaceuticals and changing regulation could affect reputation and operations 1.
- Online price transparency and dependence on third-party platforms could limit growth and reduce margins 1.
Risks
- Dependence on key customershigh
A small number of customers generates a very large share of sales, and losing one of them could seriously affect results 1.
- Recovery of receivables from the Jiuzhou pharmacyhigh
The company could face difficulties recovering receivables from the Jiuzhou pharmacy and associated clinics after the restructuring, which would significantly affect operations 1.
- Thin margins and price pressuremedium
Low margins leave little room for error, and competition could force further price cuts 1.
- Dependence on third-party online platformsmedium
Online sales rely on external platforms whose capacity or operation could limit growth 1.
- Regulatory risk in Chinamedium
Changes in rules on pharmaceutical distribution, online commerce and data protection could raise compliance costs 1.
Investment thesis
What would need to be true (bull case)
- If the online segment keeps its growth and margins improve as Allright is integrated, the company could return to operating profitability 1.
- Its position as a distributor with a very broad product range and many small customers could provide a stable revenue base 1.
- A simplified model without retail pharmacies could reduce costs and make the company more flexible 1.
What would break the thesis
- Very thin gross margins and operating losses suggest the business has not yet reached a sustainable level of profitability 1.
- Customer concentration and dependence on one supply agreement with a single pharmacy make revenue vulnerable to a change in that relationship 1.
- Larger competitors with superior resources could keep compressing prices and limit the company's growth 1.
What to watch
- Gross margin trend of the online platform and Allright salesnext 10-K
- Stability of the relationship with the Jiuzhou pharmacy and recovery of receivables2027
- Return to operating profitability in the wholesale businessnext 10-K
- Remediation of the reported internal control material weaknesses2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 31 Jul 2026; since then the company filed 6-K (09 Sept 2026), 6-K (01 Sept 2026), 6-K (28 Aug 2026), 6-K (05 Aug 2026).
The business
Ridgetech, Inc. (formerly China Jo-Jo Drugstores) is a holding company incorporated in the Cayman Islands that conducts substantially all of its operations in China 1. After the February 2025 restructuring it no longer runs retail pharmacies or herb farming, and its core activity is wholesale distribution of prescription and OTC drugs, supplements, TCM products and medical devices 1. Distribution runs both offline, to local buyers, and online, through third-party platforms and its own platform 1.
The acquisition of Ridgeline and its subsidiary Allright, closed on 28 February 2025, extended the company's online sales capacity and geographic reach; Allright is described as a fast-growing wholesale distributor with a sales network in Zhejiang Province 1. The company says its presence on several platforms gives it more opportunities to distribute nationwide 1.
Customer concentration is high: one customer accounted for 53.7% of sales from continuing operations in fiscal 2026, and sales to the Jiuzhou pharmacy are governed by a three-year supply agreement starting February 2025 1.
Segments
Market context
Pharmaceutical wholesale distribution in China is competitive and highly fragmented, with regional and national operators 1. The company states that its margins are low because it has little bargaining power on prices, and that competitors have greater logistics capacity and financial resources 1. Online sales are a fast-growing channel for medicine distribution 1.
Total revenue grew 10.2% in fiscal 2026, yet the company still reported operating losses and a net loss from continuing operations of 1.3 mn USD 1. The result depends heavily on the development of the online channel and on keeping its large customers 1.
Trends
- Growth of online salestailwind
The online channel is described as growing rapidly, and the integration of Allright added a significant contribution to revenue 1. If this growth holds, it could offset pressure on offline sales 1.
- Price pressureheadwind
Price transparency online lets customers compare offers easily, which led the company to cut prices to stay competitive and resulted in a lower margin 1.
- Dependence on one major customermixed
Sales to a single customer make up a very large part of revenue, and the relationship rests on one supply agreement, so revenue is sensitive to any change in it 1.
- Credit policy and late paymentsmixed
The company faced delayed repayments from some offline customers and chose to discontinue some credit sales, which cut offline revenue but limited receivables risk 1.
Competitive position
Competition comes from regional and national distributors, including Zhengchen Pharmaceutical, Hangzhou Xiaoran Pharmaceutical, Fengwoda Pharmaceutical and Jiuzhoutong Pharmaceutical 1. According to the company these rivals have greater logistics capacity, more financial resources and more relevant industry experience 1.
Ridgetech says some competitors have stronger relations with manufacturers and can offer larger discounts, which the company may not be able to match profitably 1. If price pressure grows, the company could have to revise its pricing structure 1.
- Zhengchen Pharmaceutical Co., Ltd.
regional wholesale pharmaceutical distributor named by the company among its competitors in China 1
- Hangzhou Xiaoran Pharmaceutical Co., Ltd.
regional distributor in the same geographic area, named among competitors 1
- Fengwoda Pharmaceutical Co., Ltd.
national pharmaceutical distribution operator, named among competitors 1
- Jiuzhoutong Pharmaceutical Co., Ltd.
national pharmaceutical distribution operator, named among competitors 1
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)09 Sept 2026
- Current report (foreign issuer)01 Sept 2026
- Current report (foreign issuer)28 Aug 2026
- Current report (foreign issuer)05 Aug 2026
- Annual report (foreign issuer)31 Jul 2026
- Current report (foreign issuer)31 Jul 2026
- Current report (foreign issuer)28 Jul 2026
- Current report (foreign issuer)21 Jul 2026
- Current report (foreign issuer)20 Jul 2026
- Current report (foreign issuer)10 Apr 2026
Sources
- [1] Form 20-F, fiscal year ended 2026-03-31 · SEC / Ridgetech, Inc. · 31 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.